gene

ALZHEIMER DISEASE

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about ALZHEIMER DISEASE: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1835Connections

1Hypotheses

30Analyses

50Outgoing

50Incoming

0Experiments

20Debates

Summary

ALZHEIMER DISEASE is a gene implicated in neurodegeneration research. Key relationships include: interacts with, activates, associated with. Associated with ALS, Aging, Als. Connected to 753 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	ALZHEIMER DISEASE
Primary Expression	Ca1, Cortex, Hippocampus
Pathways	Autophagy, Oxidative Stress, Stem Cell, Complement, Immune Response
Associated Diseases	Aging, Als, Alzheimer, Amyotrophic Lateral Sclerosis, Atherosclerosis
Known Drugs/Compounds	ANTI-AΒ ANTIBODIES, ds-cRNA
Interactions	ABCA1, ABCD3, ABI3, ACE, ACHE, ADAM10
KG Connections	1334 knowledge graph edges
Databases	GeneCards UniProt NCBI Gene HPA STRING

Pathway Diagram

graph TD
    ALZHEIMER_DISEASE["ALZHEIMER DISEASE"] -->|"therapeutic target"| Alzheimer["Alzheimer"]
    ALZHEIMER_DISEASE["ALZHEIMER DISEASE"] -->|"therapeutic target"| Ms["Ms"]
    ALZHEIMER_DISEASE["ALZHEIMER DISEASE"] -->|"therapeutic target"| Cancer["Cancer"]
    ALZHEIMER_DISEASE["ALZHEIMER DISEASE"] -->|"therapeutic target"| Diabetes["Diabetes"]
    ALZHEIMER_DISEASE["ALZHEIMER DISEASE"] -->|"activates"| Alzheimer_1["Alzheimer"]
    ALZHEIMER_DISEASE["ALZHEIMER DISEASE"] -->|"activates"| Anxiety["Anxiety"]
    TREM2["TREM2"] -->|"associated"| ALZHEIMER_DISEASE["ALZHEIMER DISEASE"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"therapeutic target"| ALZHEIMER_DISEASE["ALZHEIMER DISEASE"]
    AKT1["AKT1"] -->|"therapeutic target"| ALZHEIMER_DISEASE["ALZHEIMER DISEASE"]
    EGFR["EGFR"] -->|"therapeutic target"| ALZHEIMER_DISEASE["ALZHEIMER DISEASE"]
    style ALZHEIMER_DISEASE fill:#4a1a6b,stroke:#4fc3f7,stroke-width:2px,color:#e0e0e0

Outgoing (943)

Target	Relation	Type	Str
Alzheimer	activates	disease	1.00
Aging	associated_with	disease	1.00
Dementia	biomarker_for	disease	1.00
Neurodegeneration	associated_with	disease	1.00
Als	associated_with	disease	1.00
Alzheimer	associated_with	disease	1.00
Als	therapeutic_target	disease	1.00
Als	activates	disease	1.00
Alzheimer	therapeutic_target	disease	1.00
Neurodegeneration	therapeutic_target	disease	0.95
Inflammation	associated_with	disease	0.95
Molecular Heterogeneity	associated_with	process	0.95
Alzheimer	biomarker_for	disease	0.95
Neurodegeneration	biomarker_for	disease	0.95
Parkinson	associated_with	disease	0.95
ANTI-AΒ ANTIBODIES	targets	drug	0.90
Premature Senescence	causes	phenotype	0.90
APOE4	markers	protein	0.90
PSEN1	associated_with	gene	0.90
Amyloid Beta 42/40	markers	protein	0.90
TREM2	associated_with	gene	0.90
P-Tau	markers	protein	0.90
APOE	activates	gene	0.90
DEMENTIA	biomarker_for	gene	0.90
Autophagy	activates	pathway	0.90
ALZHEIMER	activates	gene	0.90
ALZHEIMER	associated_with	gene	0.90
Alzheimer	causes	disease	0.85
Obesity	associated_with	disease	0.85
Cancer	associated_with	disease	0.85
Aging	biomarker_for	disease	0.85
Dementia	associated_with	disease	0.85
Neuroinflammation	associated_with	disease	0.85
Neurodegeneration	activates	disease	0.85
Inflammation	therapeutic_target	disease	0.85
Aging	activates	disease	0.85
Als	biomarker_for	disease	0.85
Neurodegeneration	inhibits	disease	0.85
Blood-Brain Barrier Dysfunction	associated_with	phenotype	0.85
ABCA1	associated_with	gene	0.80
ABI3	associated_with	gene	0.80
MICROGLIAL PHAGOCYTOSIS	disrupts	pathway	0.80
TMEM106B	associated_with	gene	0.80
ACE	associated_with	gene	0.80
LRP1	associated_with	gene	0.80
Cognitive Status	disrupts	pathway	0.80
PTK2B	associated_with	gene	0.80
PICALM	associated_with	gene	0.80
SIGLEC11	associated_with	gene	0.80
SORL1	associated_with	gene	0.80

Incoming (892)

Source	Relation	Type	Str
ALZHEIMER	associated_with	gene	1.00
ALZHEIMER	therapeutic_target	gene	1.00
NEURODEGENERATION	associated_with	gene	1.00
TAU	associated_with	gene	1.00
ALZHEIMER	activates	gene	1.00
AGING	associated_with	gene	1.00
AUTOPHAGY	activates	gene	1.00
AMYLOID	activates	gene	1.00
Amyloid Probability Score 2	biomarker_for	biomarker	0.98
Blood Test	biomarker_for	biomarker	0.98
Amyloid-β	biomarker_for	biomarker	0.95
APOE*ε4	risk_factor_for	biomarker	0.95
Microglial Phagocytosis	causes	process	0.95
Amyloid-Beta Accumulation	contributes_to	phenotype	0.95
Amyloid-Beta 42	biomarker_for	protein	0.95
Amyloid-Beta 40	biomarker_for	protein	0.95
Phosphorylated Tau at Threonine 181	biomarker_for	biomarker	0.95
Aβ42:Aβ40 Ratio	biomarker_for	biomarker	0.95
Amyloid-β Accumulation	contributes_to	phenotype	0.95
AMYLOID-BETA	associated_with	protein	0.95
ISG15	implicated_in	gene	0.95
Γ-SECRETASE	involved_in	enzyme	0.95
MAPT	biomarker_for	protein	0.95
APOE ε4	risk_factor_for	protein	0.95
Oxidative Stress	contributes_to	process	0.95
TAU	biomarker_for	protein	0.95
Immune Activation	contributes_to	process	0.95
APOE	associated_with	gene	0.95
Neuritic Plaques	associated_with	phenotype	0.95
BETA-AMYLOID	biomarker_for	protein	0.95
APOE ε4 Allele	risk_factor_for	biomarker	0.95
Neurofibrillary Tangles	associated_with	phenotype	0.95
Anti-Aβ Antibodies	treats	drug	0.95
MAPT	causes	gene	0.95
Microglia	contributes_to	cell_type	0.95
Donanemab	treats	drug	0.95
AMYLOID-Β	associated_with	protein	0.95
Amyloid Reduction	therapeutic_target	mechanism	0.95
Ageing	risk_factor_for	process	0.95
Cellular Senescence	contributes_to	process	0.95
Amyloid-beta	biomarker_for	biomarker	0.95
APOE	protects_against	gene	0.95
Amyloid-Beta Plaque Deposition	biomarker_for	biomarker	0.95
P-Tau217	biomarker_for	biomarker	0.95
AMYLOID BETA	involved_in	protein	0.95
Phosphorylated Tau 217	biomarker_for	biomarker	0.95
Macrophages	contributes_to	cell_type	0.95
Neuroinflammation	associated_with	process	0.95
TAU	associated_with	protein	0.95
Mitochondrial Dysfunction	contributes_to	process	0.95

Targeting Hypotheses (1)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
APOE4-driven loss of neuronal PI(4,5)P2 bridges ganglioside-	0.380	alzheimer	Lipid metabolism dysregulation and membr

Mentioning Analyses (30)

Scientific analyses that reference this entity

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (20)

Multi-agent debates referencing this entity

Related Research

Hypotheses and analyses mentioning ALZHEIMER DISEASE in their description or question text

No additional research found

ALZHEIMER DISEASE

Understanding Entity Pages

Summary

Pathway Diagram

Outgoing (943)

Incoming (892)

Targeting Hypotheses (1)

Mentioning Analyses (30)

Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Cau

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

Allen Mouse Brain Aging Atlas: cross-age gene expression analysis

Comparative epigenetic signatures: DNA methylation age acceleration and histone

Gene Regulatory Network Inference in Alzheimer's Disease

Statistical Fine-Mapping of AD GWAS Loci to Identify Causal Variants

How do different microglial subtypes (DAM vs inflammatory vs homeostatic) transi

Is APOE4's reduced lipid binding pathogenic or a compensatory evolutionary adapt

Metabolomic signatures of neurodegeneration: metabolic reprogramming in aging br

What molecular mechanisms link elevated sphingomyelin synthase activity to incre

What molecular mechanisms enable Gal3 to enhance tau fibrillation upon binding t

How does APOE4's beneficial immune function reconcile with its established role

Why have numerous phase 3 clinical trials failed despite advances in understandi

What determines the temporal transition from protective to pathological stress g

What are the molecular signatures that distinguish protective vs. harmful microg

What are the optimal temporal windows for TREM2 inhibition vs activation in Alzh

Which specific post-translational modifications distinguish pathological from ph

What molecular mechanisms drive microglial senescence and the transition to dyst

TREM2 Therapeutic Strategy Post-INVOKE-2

Systemic immune profiling and peripheral immune contributions to neurodegenerati

Metabolomic signatures of neurodegeneration and energy metabolism dysfunction

Epigenetic reprogramming in aging neurons

Tau propagation mechanisms and therapeutic interception points

Cell type vulnerability in Alzheimer's Disease (SEA-AD data - v2)

Senescent cell clearance as neurodegeneration therapy

Extracellular vesicle biomarkers for early AD detection

Tau propagation mechanisms and therapeutic interception points

Perivascular spaces and glymphatic clearance failure in AD

Selective vulnerability of entorhinal cortex layer II neurons in AD

Perivascular spaces and glymphatic clearance failure in AD

Experiments (0)

Related Papers (0)

Debates (20)

Is microglial priming (TREM2/CX3CR1/complement-C1q) genuinely causally upstream

Debate: Chromatin Remodeling-Mediated Nutrient Sensing Restoration

Debate: TREM2 Deficiency Drives Microglial Senescence via Lipid Metabolism Dysre

Hypothesis debate: Nutrient-Sensing Epigenetic Circuit Reactivation

Epigenetic clocks as biomarkers for Alzheimer disease and neurodegeneration

How does gene expression change across age groups (young/middle/old) in hippocam

The abstract identifies dystrophic microglia as senescent cells in aged brains b

The core research question was never addressed due to missing literature content

The debate proposed biphasic TREM2 modulation but couldn't define when to switch

How do metabolomic alterations in glucose metabolism, mitochondrial function, an

Related Research